Brief: Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

LadRx

29/11/2016 11:03

Nov 29 (Reuters) - Cytrx Corp  CYTR.O : 
    * Cytrx-Reports statistically significant updated results 
from pivotal phase 3 trial of aldoxorubicin in patients with 
second-line soft tissue sarcomas 
    * Cytrx Corp - aldoxorubicin also achieves primary endpoint 
of statistically significant improvement 
    * Cytrx Corp - cytrx plans to file an nda with u.s. Fda in 
2017 
    * Cytrx- aldoxorubicin achieves primary endpoint of 
statistically significant improvement in progression-free 
survival in patients with leiomyosarcoma 
    * Cytrx Corp-aldoxorubicin achieves primary endpoint of 
statistically significant improvement in progression-free 
survival in patients with liposarcoma 
 
Source text - http://bit.ly/2fHfDZ1 
Further company coverage:  CYTR.O  
 
 ((bangalore.newsroom@thomsonreuters.com;))